Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to toludesvenlafaxine in depression patients with inadequate response to current antidepressants
ChiCTR2400080359Phase 4Not yet recruiting
- Sponsor
- Peking University Huilongguan Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toludesvenlafaxine in major depressive disorder (MDD), sponsored by Peking University Huilongguan Hospital. Primary endpoint: Montgomery-Asberg Depression Rating Scale score at week 8. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2400080359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080359.